CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival.
about
Biochemical markers in vascular cognitive impairment associated with subcortical small vessel disease - A consensus reportSveDem, the Swedish Dementia Registry - a tool for improving the quality of diagnostics, treatment and care of dementia patients in clinical practice.Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine.Levels and Age Dependency of Neurofilament Light and Glial Fibrillary Acidic Protein in Healthy Individuals and Their Relation to the Brain Parenchymal Fraction.Absence of Cerebrospinal Fluid Signs of Neuronal Injury Before and After Immediate Antiretroviral Therapy in Acute HIV Infection.Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study.Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes.Neurofilament light chain: a biomarker for genetic frontotemporal dementiaProteins that mediate protein aggregation and cytotoxicity distinguish Alzheimer's hippocampus from normal controls.Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease.Serum neurofilament light protein predicts clinical outcome in traumatic brain injury.Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorderCerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatric disordersNeurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an update.Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals.Neuroproteomics and microRNAs studies in multiple sclerosis: transforming research and clinical knowledge in biomarker research.Imaging and fluid biomarkers in frontotemporal dementia.The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer's disease clinical trials.Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies.HIV/neuroAIDS biomarkers.Biomarkers for the Early Detection and Progression of Alzheimer's Disease.Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration.Neurofilaments in CSF As Diagnostic Biomarkers in Motor Neuron Disease: A Meta-Analysis.Applying fluid biomarkers to Alzheimer's disease.Multicenter immunoassay validation of cerebrospinal fluid neurofilament light: a biomarker for neurodegeneration.Dissecting IWG-2 typical and atypical Alzheimer's disease: insights from cerebrospinal fluid analysis.The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model.Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis.Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease ProgressionMultiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development.CSF neurofilament light concentration is increased in presymptomatic CHMP2B mutation carriers.Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival.Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.Neurotransmitter deficits from frontotemporal lobar degeneration.The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias.Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum.Overexpression of MAP2 and NF-H Associated with Dendritic Pathology in the Spinal Cord of Mice Infected with Rabies Virus.Cerebrospinal fluid β-amyloid42 and neurofilament light relate to white matter hyperintensities.Neurological Complications of HIV Infection.Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum.
P2860
Q33721681-D7ACB975-A006-4C97-8D82-9F75CD9FBCF4Q35103331-06AEC415-409C-44FE-85F8-95645BB1CCCBQ35204586-1B0EB1C4-88A5-4150-BF37-33F54583625AQ35759095-DBCC0505-374E-4768-A246-F146935C8BDEQ36250205-E2A5B4E4-99FB-40D9-9D23-37C3D1CB796CQ36538745-7CAB4FD1-A07A-4D1A-9A9C-526AC6FAAD92Q36933708-1D2AE3CC-1975-4962-B76B-558C6E55342BQ37208495-713D3A28-9BAF-41B3-9E78-F22E997671BDQ37235572-0BA89020-BBEF-4FC5-B4F0-0BBF394E34B2Q37307467-01E1646D-F716-4D4C-8212-6F4514D80F3AQ37397309-EDBD44E9-F423-4EC2-95D5-A9D3DA421A8DQ37676938-A0C80EF7-EE42-4AEC-85B5-3EAFE8A6E5F7Q37703133-C92E682D-B7C0-4052-928B-EADF3C6F42E0Q38392505-1F1DE703-4923-4C5A-8235-2306172EDFA5Q38437153-A73F042D-6DFE-4F49-88D7-6AB723E9CFE0Q38610689-BD688723-40F2-419D-B558-D954D15B07AAQ38670219-ED83930C-67A2-4B79-9CB2-D9A211E69215Q38672062-DD07F3E5-0DA9-4816-9AC8-74D81266813FQ38802634-147574A1-85C9-4981-9320-35642BB71F1CQ38809646-70D81D40-A8B9-4C61-8B76-DE7279A494CCQ38979999-72E02176-EEAF-40EE-AA4A-D2ED85A788C1Q39029436-AEE5DABA-7E99-4D84-A6F3-151A3ABF140EQ39103639-5437BB9B-F5AC-4356-B68B-5A43E1EA7EA3Q39251035-95398D0A-50D0-4264-B648-76DC791B5B27Q39339614-064718AA-CBBE-4A62-98E8-51935B58EE1DQ39342351-CA5663AA-5BE0-49EA-968E-B5E29AE4EE0EQ39432793-84FD317A-95A4-4DAC-9A5B-9C27A549E84EQ40047133-AD12EABF-CE6C-4C09-A94E-40A2A3841124Q42287644-83B221E2-C855-46DC-8FE8-7D06AE5D3380Q42656279-5E35D967-4616-40AE-9DB1-3AF16044748FQ47315423-5B09ADCB-17C5-49E6-8133-91FAE6EF672CQ47341318-C8F96AE8-31D5-48B4-BDE7-782C5CF24AF6Q47587631-9A894DCF-9812-46A0-8F57-FF3D59CCD80CQ47837913-FF1C0FCA-11DD-43DD-AA4F-6B7E2A321CCEQ48168855-B80EBCB0-F783-4075-A7D3-31DDB906DE20Q48730030-FAF11E22-D8C7-4F51-A47B-9D02E8640820Q51735885-EE63322A-0DF4-4A19-A941-CA5BBCAED6A4Q52558592-01B27233-E96A-410A-8A9F-DC56DD6321B2Q52774286-2421302E-018A-43A1-9E84-0E4F4A29F7E9Q53396239-76FCB05A-C35D-4330-818E-27B3494523CA
P2860
CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
CSF neurofilament light differ ...... redicts severity and survival.
@en
CSF neurofilament light differ ...... redicts severity and survival.
@nl
type
label
CSF neurofilament light differ ...... redicts severity and survival.
@en
CSF neurofilament light differ ...... redicts severity and survival.
@nl
prefLabel
CSF neurofilament light differ ...... redicts severity and survival.
@en
CSF neurofilament light differ ...... redicts severity and survival.
@nl
P2093
P50
P1433
P1476
CSF neurofilament light differ ...... redicts severity and survival.
@en
P2093
Bahman Farahmand
Christoffer Rosén
Jonathan M Schott
Lena Kilander
P304
P356
10.1212/WNL.0000000000001015
P407
P50
P577
2014-10-22T00:00:00Z